BioStrand Omics Analysis Blog:
ML

AI-powered genomics to advance precision medicine

Dr Ingrid Brands, CEO | July 27, 2022

Sir William Osler, often called the father of modern medicine, was among the first to articulate a ...

AI, NLP and the ROI of drug development

Dr Ingrid Brands, CEO | July 20, 2022

The out-of-pocket R&D costs of developing a single drug, whether successfully launched or not, are...

Accelerating pharma R&D and innovation through technology partnerships

Dr Ingrid Brands, CEO | July 13, 2022

Biopharmas are increasingly turning to alliances & partnerships to drive external innovation....

Improving Drug Safety with Adverse Event Detection Using NLP

Dr Ingrid Brands, CEO | June 15, 2022

It is estimated that Adverse Events (AEs) are likely one of the 10 leading causes of death and...

A Hybrid Approach to NLP in Drug Discovery

Dr Ingrid Brands, CEO | June 8, 2022

Artificial Intelligence-powered technologies like NLP are becoming critical to the pharmaceutical...

Subscribe to our blog

AI in early phase drug development

Dr Ingrid Brands, CEO | June 1, 2022

AI technologies are currently the most disruptive trend in the pharmaceutical industry. Over the...

Efficient data integration is the key to effective AI/ML

Dr Ingrid Brands, CEO | May 18, 2022

AI/ML technologies can be notoriously data-hungry with the broader concern being that certain...

Knowledge Graphs & The Power Of Context

Dr Ingrid Brands, CEO | April 20, 2022

Data overload is becoming a real challenge for businesses of all stripes even as a majority...

AI, ML, DL, and NLP: An Overview

Dr Ingrid Brands, CEO | April 13, 2022

Today artificial intelligence (AI), machine learning (ML), deep learning (DL) and natural language...

AI in drug development - from hype to reality

Dr Ingrid Brands, CEO | March 16, 2022

Back in 1981, a Discovery magazine article called Designing Drugs With Computers detailed a...